Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer

Stefan Glück, Gunter von Minckwitz, Michael Untch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The proportion of elderly women in the population is rising, and in tandem, the incidence of breast cancer rises with age. Because of health and tolerability concerns, as well as life expectancy, physicians may be reluctant to advise a standard treatment regimen for elderly patients with metastatic breast cancer. To elucidate this issue, we performed a literature review of clinical studies that included women with metastatic breast cancer who were over the age of 65. Our results show that although little clinical evidence exists, what is available suggests that standard treatment is tolerated and beneficial for patients meeting certain criteria. A geriatric assessment may identify specific patient groups (independent, dependent, or frail) and thereby guide treatment. Treatment recommendations for elderly patients with metastatic breast cancer are sparse, although first-line endocrine treatment, usually aromatase inhibitors or tamoxifen, is recommended for hormone-sensitive disease. In general, the evidence from clinical studies suggests that aromatase inhibitors are more effective than either tamoxifen or megestrol acetate as first- or second-line treatment in postmenopausal women with metastatic breast cancer. Ultimately, quality of life, treatment effects, and comorbidities are important aspects in this population and may guide treatment choice. To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years.

Original languageEnglish
Pages (from-to)142-149
Number of pages8
JournalBreast
Volume22
Issue number2
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Therapeutics
Tamoxifen
Megestrol Acetate
Geriatric Assessment
Life Expectancy
Population
Comorbidity
Quality of Life
Clinical Trials
Hormones
Physicians
Incidence

Keywords

  • Antineoplastic agents
  • Aromatase inhibitors
  • Breast cancer
  • Elderly
  • Exemestane
  • Hormonal
  • Metastatic
  • Tamoxifen

ASJC Scopus subject areas

  • Surgery

Cite this

Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. / Glück, Stefan; von Minckwitz, Gunter; Untch, Michael.

In: Breast, Vol. 22, No. 2, 01.04.2013, p. 142-149.

Research output: Contribution to journalArticle

Glück, Stefan ; von Minckwitz, Gunter ; Untch, Michael. / Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. In: Breast. 2013 ; Vol. 22, No. 2. pp. 142-149.
@article{a0906eaf99f8486dbad60df79e90fe81,
title = "Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer",
abstract = "The proportion of elderly women in the population is rising, and in tandem, the incidence of breast cancer rises with age. Because of health and tolerability concerns, as well as life expectancy, physicians may be reluctant to advise a standard treatment regimen for elderly patients with metastatic breast cancer. To elucidate this issue, we performed a literature review of clinical studies that included women with metastatic breast cancer who were over the age of 65. Our results show that although little clinical evidence exists, what is available suggests that standard treatment is tolerated and beneficial for patients meeting certain criteria. A geriatric assessment may identify specific patient groups (independent, dependent, or frail) and thereby guide treatment. Treatment recommendations for elderly patients with metastatic breast cancer are sparse, although first-line endocrine treatment, usually aromatase inhibitors or tamoxifen, is recommended for hormone-sensitive disease. In general, the evidence from clinical studies suggests that aromatase inhibitors are more effective than either tamoxifen or megestrol acetate as first- or second-line treatment in postmenopausal women with metastatic breast cancer. Ultimately, quality of life, treatment effects, and comorbidities are important aspects in this population and may guide treatment choice. To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years.",
keywords = "Antineoplastic agents, Aromatase inhibitors, Breast cancer, Elderly, Exemestane, Hormonal, Metastatic, Tamoxifen",
author = "Stefan Gl{\"u}ck and {von Minckwitz}, Gunter and Michael Untch",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.breast.2012.12.015",
language = "English",
volume = "22",
pages = "142--149",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer

AU - Glück, Stefan

AU - von Minckwitz, Gunter

AU - Untch, Michael

PY - 2013/4/1

Y1 - 2013/4/1

N2 - The proportion of elderly women in the population is rising, and in tandem, the incidence of breast cancer rises with age. Because of health and tolerability concerns, as well as life expectancy, physicians may be reluctant to advise a standard treatment regimen for elderly patients with metastatic breast cancer. To elucidate this issue, we performed a literature review of clinical studies that included women with metastatic breast cancer who were over the age of 65. Our results show that although little clinical evidence exists, what is available suggests that standard treatment is tolerated and beneficial for patients meeting certain criteria. A geriatric assessment may identify specific patient groups (independent, dependent, or frail) and thereby guide treatment. Treatment recommendations for elderly patients with metastatic breast cancer are sparse, although first-line endocrine treatment, usually aromatase inhibitors or tamoxifen, is recommended for hormone-sensitive disease. In general, the evidence from clinical studies suggests that aromatase inhibitors are more effective than either tamoxifen or megestrol acetate as first- or second-line treatment in postmenopausal women with metastatic breast cancer. Ultimately, quality of life, treatment effects, and comorbidities are important aspects in this population and may guide treatment choice. To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years.

AB - The proportion of elderly women in the population is rising, and in tandem, the incidence of breast cancer rises with age. Because of health and tolerability concerns, as well as life expectancy, physicians may be reluctant to advise a standard treatment regimen for elderly patients with metastatic breast cancer. To elucidate this issue, we performed a literature review of clinical studies that included women with metastatic breast cancer who were over the age of 65. Our results show that although little clinical evidence exists, what is available suggests that standard treatment is tolerated and beneficial for patients meeting certain criteria. A geriatric assessment may identify specific patient groups (independent, dependent, or frail) and thereby guide treatment. Treatment recommendations for elderly patients with metastatic breast cancer are sparse, although first-line endocrine treatment, usually aromatase inhibitors or tamoxifen, is recommended for hormone-sensitive disease. In general, the evidence from clinical studies suggests that aromatase inhibitors are more effective than either tamoxifen or megestrol acetate as first- or second-line treatment in postmenopausal women with metastatic breast cancer. Ultimately, quality of life, treatment effects, and comorbidities are important aspects in this population and may guide treatment choice. To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years.

KW - Antineoplastic agents

KW - Aromatase inhibitors

KW - Breast cancer

KW - Elderly

KW - Exemestane

KW - Hormonal

KW - Metastatic

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84875509057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875509057&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2012.12.015

DO - 10.1016/j.breast.2012.12.015

M3 - Article

VL - 22

SP - 142

EP - 149

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2

ER -